Literature DB >> 1510692

The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?

N Robertson1, I J Stratford, S Houlbrook, J Carmichael, G E Adams.   

Abstract

15 human tumour cell lines (lung, breast and colon) have been evaluated for their sensitivity to the quinone based anti-cancer drugs Mitomycin C, Porfiromycin, and EO9 (3-hydroxymethyl-5-aziridinyl-1-methyl-2-(IH-indole-4,7-dione)prop-beta- en-alpha-ol). Sensitivity has been compared with the intra-cellular levels of DT-diaphorase, an enzyme thought to be important in the reductive activation of these quinones. No correlation exists between levels of DT-diaphorase and sensitivity to Mitomycin C or Porfiromycin. However, for EO9 those cell lines showing highest levels of DT-diaphorase activity tend to be the most sensitive.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510692     DOI: 10.1016/0006-2952(92)90429-m

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  21 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9.

Authors:  J D Jonkman-de Vries; J J Kettenes-van den Bosch; R E Henrar; A Bult; J H Beijnen
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 3.  Calcium and reactive oxygen species in acute pancreatitis: friend or foe?

Authors:  David M Booth; Rajarshi Mukherjee; Robert Sutton; David N Criddle
Journal:  Antioxid Redox Signal       Date:  2011-08-23       Impact factor: 8.401

4.  Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9.

Authors:  J D Jonkman-de Vries; H Talsma; R E Henrar; J J Kettenes-van den Bosch; A Bult; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 5.  EO9 (Apaziquone): from the clinic to the laboratory and back again.

Authors:  Roger M Phillips; Hans R Hendriks; Godefridus J Peters
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

6.  Hsp90 inhibition: elimination of shock and stress.

Authors:  Adam S Duerfeldt; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2010-07-01       Impact factor: 2.823

7.  Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.

Authors:  D L Gustafson; H D Beall; E M Bolton; D Ross; C A Waldren
Journal:  Mol Pharmacol       Date:  1996-10       Impact factor: 4.436

Review 8.  DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C.

Authors:  D Ross; D Siegel; H Beall; A S Prakash; R T Mulcahy; N W Gibson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 9.  Cellular approaches to bioreductive drug mechanisms.

Authors:  A M Rauth; R S Marshall; B L Kuehl
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 10.  The experimental development of bioreductive drugs and their role in cancer therapy.

Authors:  P Workman; I J Stratford
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.